Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Ruihua Xu, ProfessorRecruiting - Henan Cancer Hospital
Zhengzhou, Henan, China
Recruiting - the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Recruiting - Liaoning Cancer Hosptial & Institute
Shenyang, Liaoning, China
Recruiting - the Second People'S Hospital of Sichuan
Chengdu, Sichuan, China
Recruiting - Chinese Pla General Hospital
Beijing, China
Recruiting - First Affiliated Hospital of Pla General Hospital
Beijing, China
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2013
- Primary completion
- 31 Aug 2017
- Completion
- —
- Last update posted
- 28 Apr 2014
- Registered enrollment
- 600
- Registry id
- NCT01912443
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.